{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:30:27Z","timestamp":1753893027849,"version":"3.41.2"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Artif. Intell."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Chronic pain affects approximately 30% of the global population, posing a significant public health challenge. Despite their widespread use, traditional pharmacological treatments, such as opioids and NSAIDs, often fail to deliver adequate, long-term relief while exposing patients to risks of addiction and adverse side effects. Given these limitations, medical cannabis has emerged as a promising therapeutic alternative with both analgesic and anti-inflammatory properties. However, its clinical efficacy is hindered by high interindividual variability in treatment response and elevated dropout rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive dataset integrating genetic, clinical, and pharmacological information was compiled from 542 Caucasian patients undergoing cannabis-based treatment for chronic pain. A machine learning (ML) model was developed and validated to predict therapy dropout. To identify the most influential factors driving dropout, SHapley Additive exPlanations (SHAP) analysis was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The random forest classifier demonstrated robust performance, achieving a mean accuracy of 80% and a maximum of 86%, with an AUC of 0.86. SHAP analysis revealed that high final VAS scores and elevated THC dosages were the most significant predictors of dropout, both strongly correlated with an increased likelihood of discontinuation. In contrast, baseline therapeutic benefits, CBD dosages, and the CC genotype of the rs1049353 polymorphism in the CNR1 gene were associated with improved adherence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our findings highlight the potential of ML and pharmacogenetics to personalize cannabis-based therapies, improving adherence and enabling more precise management of chronic pain. This research paves the way for the development of tailored therapeutic strategies that maximize the benefits of medical cannabis while minimizing its side effects.<\/jats:p><\/jats:sec>","DOI":"10.3389\/frai.2025.1557894","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T06:37:57Z","timestamp":1740033477000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting therapy dropout in chronic pain management: a machine learning approach to cannabis treatment"],"prefix":"10.3389","volume":"8","author":[{"given":"Anna","family":"Visibelli","sequence":"first","affiliation":[]},{"given":"Rebecca","family":"Finetti","sequence":"additional","affiliation":[]},{"given":"Bianca","family":"Roncaglia","sequence":"additional","affiliation":[]},{"given":"Paolo","family":"Poli","sequence":"additional","affiliation":[]},{"given":"Ottavia","family":"Spiga","sequence":"additional","affiliation":[]},{"given":"Annalisa","family":"Santucci","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2217\/pmt-2020-0110","article-title":"Cannabis-based medicines and pain: a review of potential synergistic and entourage effects","volume":"11","author":"Anand","year":"2021","journal-title":"Pain Manag."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.3390\/cimb45040228","article-title":"Cannabis pharmacogenomics: a path to personalized medicine","volume":"45","author":"Babayeva","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/14737175.2023.2181696","article-title":"Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: a cohort study","volume":"23","author":"Bapir","year":"2023","journal-title":"Expert. Rev. Neurother."},{"key":"ref4","first-page":"2","article-title":"Validity and reliability of Visual Analogue Scale (VAS) for pain measurement","volume":"2","author":"Begum","year":"2019","journal-title":"J. Med. Case Rep. Rev."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1016\/j.pain.2014.09.014","article-title":"Cut-off points for mild, moderate, and severe pain on the Visual Analogue Scale for pain in patients with chronic musculoskeletal pain","volume":"155","author":"Boonstra","year":"2014","journal-title":"Pain"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach. Learn."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"626853","DOI":"10.3389\/fpubh.2021.626853","article-title":"Evaluation of patient reported safety and efficacy of cannabis from a survey of medical cannabis patients in Canada","volume":"9","author":"Cahill","year":"2021","journal-title":"Front. Public Health"},{"key":"ref9","first-page":"27","article-title":"Cannabis and neuropsychiatric disorders: an updated review","volume":"28","author":"Chayasirisobhon","year":"2019","journal-title":"Acta Neurol. Taiwan"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.15585\/mmwr.mm6736a2","article-title":"Prevalence of chronic pain and high-impact chronic pain among adults\u2014United States, 2016","volume":"67","author":"Dahlhamer","year":"2018","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e088","DOI":"10.5435\/JAAOSGlobal-D-17-00088","article-title":"Validation of Digital Visual Analog Scale pain scoring with a traditional paper-based visual analog scale in adults","volume":"2","author":"Delgado","year":"2018","journal-title":"J. Am. Acad. Orthop. Surg. Glob. Res. Rev."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.amjmed.2019.05.017","article-title":"Cannabis and cannabinoids: kinetics and interactions","volume":"132","author":"Foster","year":"2019","journal-title":"Am. J. Med."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.2174\/1568026622666221006140825","article-title":"Artificial intelligence approaches in drug discovery: towards the laboratory of the future","volume":"22","author":"Frusciante","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"ref15","first-page":"53","article-title":"Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study","volume":"38","author":"Giorgi","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.procs.2021.08.174","article-title":"Caregiver matcher: graph neural networks for connecting caregivers of rare disease patients","volume":"192","author":"Guerranti","year":"2021","journal-title":"Procedia Comput. Sci."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/17512433.2022.2017771","article-title":"UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions","volume":"15","author":"Harris","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41467-020-17945-4","article-title":"How machine learning can help select capping layers to suppress perovskite degradation","volume":"11","author":"Hartono","year":"2020","journal-title":"Nat. Commun."},{"volume-title":"Relieving pain in America: a blueprint for transforming prevention, care, education, and research","year":"2011","key":"ref20"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.26828\/cannabis\/2023\/000149","article-title":"Perceived effectiveness of medical cannabis among adults with chronic pain: findings from interview data in a three-month pilot study","volume":"6","author":"McMahon","year":"2023","journal-title":"Cannabis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e27343","DOI":"10.1097\/MD.0000000000027343","article-title":"Associations of CB1 cannabinoid receptor (CNR1) gene polymorphisms","volume":"100","author":"Pabalan","year":"2021","journal-title":"Medicine"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1186\/s42238-020-00033-1","article-title":"Pharmacogenetic-guided cannabis usage in the community pharmacy: evaluation of a pilot program","volume":"2","author":"Papastergiou","year":"2020","journal-title":"J. Cannabis Res."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3390\/genes13101832","article-title":"The pharmacogenetics of cannabis in the treatment of chronic pain","volume":"13","author":"Poli","year":"2022","journal-title":"Genes"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1097\/j.pain.0000000000001939","article-title":"The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises","volume":"161","author":"Raja","year":"2020","journal-title":"Pain"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/phar.2115","article-title":"Cannabis for chronic pain: challenges and considerations","volume":"38","author":"Romero-Sandoval","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14737175.2023.2195551","article-title":"Clinical outcome data of chronic pain patients treated with cannabis-based oils and dried flower from the UK Medical Cannabis Registry","volume":"23","author":"Tait","year":"2023","journal-title":"Expert. Rev. Neurother."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/j.pain.0000000000001384","article-title":"Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11)","volume":"160","author":"Treede","year":"2019","journal-title":"Pain"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3390\/biomedicines11071776","article-title":"Supporting machine learning model in the treatment of chronic pain","volume":"11","author":"Visibelli","year":"2023","journal-title":"Biomedicines"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3389\/fphar.2018.01259","article-title":"Cannabinoids and pain: new insights from old molecules","volume":"9","author":"Vu\u010dkovi\u0107","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e3072","DOI":"10.1002\/brb3.3072","article-title":"Assessment of clinical outcomes in patients with fibromyalgia: analysis from the UK Medical Cannabis Registry","volume":"13","author":"Wang","year":"2023","journal-title":"Brain Behav."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"n1034","DOI":"10.1136\/bmj.n1034","article-title":"Medical cannabis or cannabinoids for chronic non-cancer and cancer-related pain: a systematic review and meta-analysis of randomised clinical trials","volume":"374","author":"Wang","year":"2021","journal-title":"BMJ"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e054282","DOI":"10.1136\/bmjopen-2021-054282","article-title":"Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies","volume":"12","author":"Zeraatkar","year":"2022","journal-title":"BMJ Open"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/sj.mp.4001560","article-title":"Human cannabinoid receptor 1: 5\u2032 exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse","volume":"9","author":"Zhang","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression Scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"container-title":["Frontiers in Artificial Intelligence"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frai.2025.1557894\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T06:38:01Z","timestamp":1740033481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frai.2025.1557894\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":33,"alternative-id":["10.3389\/frai.2025.1557894"],"URL":"https:\/\/doi.org\/10.3389\/frai.2025.1557894","relation":{},"ISSN":["2624-8212"],"issn-type":[{"type":"electronic","value":"2624-8212"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"article-number":"1557894"}}